Corporate OverviewApril 2017

NON-CONFIDENTIAL

2

Internal Pipeline - to be licensed to a partner after POC

• Lead product candidate, Ovarest™ (oral leuprolide tablet)• Initial indication: Endometriosis• Phase 2A starting Q2 2017 (POC)• Estimated at >$600M in the United States for endometriosis only

• Tobrate™ (oral tobramycin tablet) - fast track and QIDP status granted by FDA• Initial indication uUTI• Currently in formulation optimization• Estimated at >$400M in the United States for uUTI

Clinical / Commercial Tablet Manufacturing

• Experienced formulation development and clinical trial manufacturer supporting our partners from feasibility through Phase 2 clinical trial supplies, including analytical development and stability testing

• Currently developing the capability for Phase 3 and commercial manufacturing of products utilizing our formulation technology.

Peptelligence™ PlatformProprietary, Cutting-Edge Oral Drug Delivery Technology

• Novel formulation technology enables oral delivery of molecules that are typically injected, including peptides and BCS class II, III, and IV small molecules

• Robust IP protection in the U.S. and abroad through 2030

Feasibility-to-Licensing Partnering Program

• Most advanced projects using our oral drug delivery technology:• Tarsa Therapeutics – NDA submitted for TBRIA™ in osteoporosis• Cara Therapeutics – Phase 2B initiated Q3 2016 in chronic pain

(osteoarthritis) and Phase 1 uremic pruritus data expected this quarter• Ferring Pharmaceuticals – License agreement to develop an oral formulation

executed Q1 2017

Enteris BioPharmaOverview

3

Leadership History• Joel Tune

Executive Chairman & Chief Executive Officer 35+ years of pharma, medtech and biotech experience Extensive management experience in product development,

sales and marketing, strategy, M&A and general management Successfully completed more than 20 business development

transactions for Baxter Healthcare’s Medication DeliveryGroup

• Brian ZietsmanPresident & Chief Financial Officer 25+ years of strategic finance and accounting experience Diverse financial capacities with public and private

pharma/biotech companies

• Paul Shields, Ph.D.Chief Operating Officer 24+ years in the biopharma industry Extensive Chemistry, Manufacturing, and Controls (CMC)

experience

Enteris BioPharmaExecutive Leadership

Overview of Peptelligence™Intelligent Solutions for Oral Drug Delivery™

4

• Reduces peptide degradation

• Increases paracellular transport

• No modification of the peptide required

• Permeation enhancer acts as a surfactant

• Paracellular transport bypasses transcellular permeation hurdles

5

Oral Peptide Delivery Challenges• GI tract degrades and digests

peptides• Low permeability through the

intestinal cell layer

Oral Small Molecule Delivery Challenges• Solubility or dissolution with

limited absorption• Poor permeability due to

interaction with efflux transporters or other mechanisms

Peptelligence™ Solution

Peptelligence™ The Peptelligence™ Solution

6

Increases product uptake & use vs. parenteral administration

• Increases physician starts• Improves patient compliance• Expands indications

Protects & extends product exclusivity & commercial life

• Provides compelling differentiation in competitive markets

• Adds extra layer of robust IP protection through 2030

Mechanism for Oral Drug Delivery

Enteric coat prevents tablet from opening in stomach at low pH

API absorbed across intestinal wall via paracellular transport

Enteric coat dissolves at neutral pH in the small intestine

Protease inhibitor, permeability enhancers and API released

Peptellgence™Mechanism for Oral Drug Delivery

Abso

lute

Bio

avai

labi

lity

(%)

Molecular Weight (Da)7

The Enteris technology has enabledthe oral delivery of several peptidesand small molecules across a rangeof physical and chemical properties.

Bioavailability data from dogs

Peptellgence™Bioavailability Across a Range of Molecular Weights

8Enteris has conducted more than 25 pre-clinical feasibility programs

NON-CONFIDENTIAL

Peptellgence™Clinical Development Pipeline

9

Robust IP Protection

9 issued U.S. patents2 allowed U.S. patent applications

3 pending U.S. provisional patent applications

Key issued patents extend through at least 2030

29 issued Foreign patents5 pending Foreign patent applications

Peptellgence™Patent Portfolio

Enteris Clinical AssetsInnovative Oral Therapeutics for Women’s Health

10

11

Peptelligence™ Solution • Ovarest™ (oral leuprolide tablet), our leading product candidate isbeing evaluated for its potential to treat endometriosis

• Extensive market research and clinician feedback indicates thatdaily oral leuprolide tablet would offer patient friendly alternative tomonthly depot injections and drive Ovarest™ use early and moreoften

• Estimated at >$600M in the United States for endometriosis

Clinical Development • Crossover PK/food effect Phase 1 study completed in 14 healthyvolunteers

• Phase 2a parallel group PK/PD study in 38 healthy volunteers to beinitiated Q1 2017

Need • 6 million U.S. women have endometriosis• Limited efficacy with oral and injectable hormonal contraception• LUPRON DEPOT® (leuprolide acetate for depot suspension) most

efficacious treatment; No oral formulation exists on the market

Ovarest™Oral Leuprolide Tablet for the Treatment of Endometriosis

12*This plan has incorporated FDA (DBRUP) recommendations per PIND Meeting 125004 held on Dec. 15, 2014.

Phase 1Crossover PK/Food Effect study in 14 healthy volunteers

2 Ovarest doses vs 1 mg SC

Phase 2aParallel group

PK/PD study in 38 healthy volunteers

4 mg tablet QD; 4 mg tablet BID; depot for 1 month

Phase 3Parallel-group, placebo-controlled, double-blind studies in women with

endometriosis

Registration Trials (Two Phase 3 Efficacy/Safety Studies)Human POC: PK

PK/PD Modeling

PK/PD Bridging to Lupron Depot®

Ovarest™Clinical Development Plan

Complete Study Start: Q2 2017Data Read out: Q4 2017

13

Peptelligence™ Solution • Tobrate™ (oral tobramycin tablet) is being evaluated for its potentialto treat uUTI

• Tobramycin is an ideal candidate for uUTI as it concentrates in theurine after dosing – enables lower dose

• Low dose / short duration improves safety profile• Estimated at >$400M in sales in the United States, even as

primarily a second line agent

Clinical Development • Fast track and QIDP status granted by FDA• Currently in formulation optimization.

Need • Uncomplicated urinary tract infections (uUTI) are highly prevalent,affecting 10 million U.S. women each year

• Currently available first-line therapies are becoming increasinglyineffective due to antibiotic resistance

• Tobramycin, which has minimal resistance issues, is available in avariety of dosage forms but no oral formulation exists on the market

Tobrate™Oral Tobramycin Tablet for the Treatment of uUTI

Partner Clinical AssetsProviding Advanced Oral Formulation Solutions to Build Long-Term, Strategic Partnerships

14

15

Enteris BioPharmaPartners Receive

The only technology in the industry that has demonstrated broad

applicability, effectiveness, and scalability

Manufacturing expertise and infrastructure to scale production up to small commercial scale

The only technology with predictable performance: reliable estimation of likelihood of success based on API

physical-chemical properties

Peptellgence™Key Differentiators

• GMP facility• Strong inspection history (no 483s

issued in last 3 FDA inspections)• Most recent inspection: Jan. 2016

• Manufacture of Phase 1 and 2 clinical trial material

• Developing capacity for 50-250kg commercial batches

• Dedicated R&D, process development, tableting and film-coating suites

• Full QA/QC

• Analytical development, release and stability

16

Peptellgence™Clinical Trial / Commercial Tablet Manufacturing Capability

17

Peptelligence™ Solution • TBRIA™ employs our proprietary technology, allowing for once-daily oral delivery of calcitonin

• Provides a more convenient route of administration for patients andmay result in better patient compliance

Clinical Development • Phase 3 ORACAL trial showed TBRIA™ was superior to both nasalcalcitonin spray and placebo in increasing bone mineral densityafter 48 weeks

• NDA submitted in October 2015 for the treatment ofpostmenopausal osteoporosis in women greater than 5 yearspostmenopause when alternative treatments unsuitable

Need • Injectable and intranasal calcitonin has been used for the treatmentof osteoporosis for more than 35 years

• Osteoporosis patients either abandon or are reluctant to initiatetreatment due to medication interfering with their lives or side effectconcerns

Tarsa Therapeutics & TBRIA™Overview

18

Peptelligence™ Solution • Oral CR845 tablet formulation synthesized using our proprietaryPeptelligence™ technology platform

• Oral delivery of peripherally selective kappa opioid agonist haspotential to provide continuity of care for acute and chronic painpatients

Clinical Development • Positive Phase 2a for OA trial results reported in Q4 2015• Double-blind, placebo-controlled Phase 2b for OA trial initiated

September 2016

Need • Currently marketed opioids inhibit intestinal transit and carry a riskof causing addiction and life-threatening respiratory depression

• 79% of patients report adverse events from pain medications –most adverse events are opioid-related

• Significant need among osteoarthritis (OA) and general chronic painpatients for new treatment options

Cara Therapeutics & Oral CR845™Osteoarthritis and General Chronic Pain

• Confirmed Analgesic Exposure at 1mg-5mg Tablet Strength• Well Tolerated –No SAEs on Single or Repeat Dose (6 day b.i.d.)

19

Cara Therapeutics & Oral CR845™Phase 1b Study Data

20

5.0 mg Dose Group • 50% reported at least a 30% reduction in pain score at the end oftreatment period

• Integrated AUC analysis of overall NRS score indicated a significantreduction compared to lower doses (Wilcoxon Rank Sum Test:p=0.02)

• Pain score reduction accompanied by a significant reduction inmean rescue medication of approximately 80% (ANOVA: p=0.02)

• 59% of patients used no rescue medication in Week 2• Dose effectiveness was further supported by significant, dose-

related increases in the proportion of patients whose OA was "verymuch improved" or "much improved” (Cochran-Mantel-Haenszeltest, p=0.02, 2-sided)

Overall • Dose-related reduction in mean joint pain score (NRS) after two-weeks, ranging from -25% (0.25 mg) to -34% (5.0 mg)

• All four tablet strengths observed to be safe and well tolerated

Cara Therapeutics & Oral CR845™Positive Top-Line Results in Phase 2a Osteoarthritis Study

21

Peptelligence™ Solution • Oral CR845 tablet formulation synthesized using our proprietaryPeptelligence™ technology platform

Clinical Development • Phase 1 trial for pruritus initiated in October 2016 in hemodialysispatients

Need • Uremic pruritus (UP) is an intractable systemic itch condition thatoccurs with the greatest frequency and intensity in chronic kidneydisease

• Prevalence of UP to be approximately 40 percent of patients withend-stage renal disease (ESRD), with approximately 24 percent ofpatients reporting severe pruritus.

• Moderate-to-severe chronic pruritus has repeatedly been shown todirectly decrease quality of life, contribute to symptoms that impairquality of life (such as poor sleep quality), and is associated withdepression.

Cara Therapeutics & Oral CR845™Uremic Pruritus

Thank You!